2022
Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group
Tan W, Steinberg G, Witjes J, Li R, Shariat S, Roupret M, Babjuk M, Bivalacqua T, Psutka S, Williams S, Cookson M, Palou J, Kamat A. Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. European Urology Oncology 2022, 5: 505-516. PMID: 35718695, DOI: 10.1016/j.euo.2022.05.005.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerInternational Bladder Cancer GroupBladder cancer groupManagement of patientsIntermediate-riskIntravesical treatmentCancer groupRisk factorsClinical trialsIntravesical chemotherapyMultifocal tumorsEarly recurrenceTumor sizeBladder cancerFrequent recurrenceHeterogeneous diseaseGrading systemCarcinoma in situStage of tumorPostoperative intravesical chemotherapyRandomized clinical trialsMaintenance BCGComparison of outcomesRecurrent diseaseClinical practice guidance
2010
[Risk factors of novel severe influenza A(H1N1) with concurrent adult respiratory distress syndrome].
Dai B, Kang J, Wang Z, Kong D, Tan W, Zhao H. [Risk factors of novel severe influenza A(H1N1) with concurrent adult respiratory distress syndrome]. National Medical Journal Of China 2010, 90: 2392-5. PMID: 21092507.Peer-Reviewed Original ResearchConceptsAdult respiratory distress syndromeT lymphocyte subsetsSevere influenza AMultivariate logistic regression analysisNon-ARDS groupInfluenza ANon-smoking groupLogistic regression analysisStatistically significant differenceRisk factorsIncidence of adult respiratory distress syndromeAdult respiratory distress syndrome patientsNovel influenza APatient lymphocyte countsRespiratory distress syndromeSignificant differenceControlled clinical trialsLactate dehydrogenaseRegression analysisDistress syndromeLymphocyte countClinical featuresRetrospective analysisClinical trialsH1N1